Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.

about

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.

Item

http://www.wikidata.org/entity/Q40119164

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Reply: Cost-effectiveness of c ...... nfection in the United States.

@en

type

Item

label

Reply: Cost-effectiveness of c ...... nfection in the United States.

@en

prefLabel

Reply: Cost-effectiveness of c ...... nfection in the United States.

@en

P1476

Reply: Cost-effectiveness of c ...... infection in the United States

@en

P2093

Boris Gorsh

http://www.w3.org/2001/XMLSchema#string

Bruce Sill

http://www.w3.org/2001/XMLSchema#string

Divya Moorjaney

http://www.w3.org/2001/XMLSchema#string

Shalini Hede

http://www.w3.org/2001/XMLSchema#string

Yong Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.

Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.

Economic model of a birth cohort screening program for hepatitis C virus.

P304

1123-1125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13696998.2017.1360313

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael L Ganz

Catherine Saint-Laurent Thibault

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28745536

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir